Use of pcs6422 and capecitabine to treat cancer.
CL202600068A1Pending Publication Date: 2026-07-10PROCESSA PHARMACEUTICALS INC
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- CL202600068
- Authority / Receiving Office
- CL · CL
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-07-12
- Filing Date
- 2026-01-09
- Publication Date
- 2026-07-10
Abstract
This disclosure provides, among other things, customized methods for administering PCS6422 and capecitabine in combination, customized methods of cancer treatment, and methods for determining the frequency of (i) administration of PCS6422 and capecitabine or (ii) administration of capecitabine in a subject.
Need to check novelty before this filing date? Find Prior Art